Matthew Schabath, PhD

Articles by Matthew Schabath, PhD

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

ByChia Jie Tan,Connor Willis,Trang Au,Matthew Schabath, PhD,Chenghui Li,Kristen Kelley,Xiaoqing Xu,Leah Park,Clara Lam,Sandhya Mehta,Jackie Kwong,Diana Brixner,David Stenehjem

April 17th 2025

Matthew Schabath, PhD, on COLORS Training for Oncologists Treating LGBTQ+ Individuals

ByMatthew Schabath, PhD

September 26th 2022

At 2022 ASCO, Matthew Schabath, PhD, discussed the COLORS training designed to improve cultural sensitivity amongst oncologists treating patients within the LGBTQ+ community.

Matthew Schabath, PhD

Articles by Matthew Schabath, PhD

97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer

Matthew Schabath, PhD, on COLORS Training for Oncologists Treating LGBTQ+ Individuals

Latest Updated Articles

Trending on CancerNetwork

How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?

64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC

Comprehensive Cancer Database May Enhance Personalized Therapy

Single-Agent PD-1 Blockade Therapy Improves Responses in Desmoplastic Melanoma

FDA Grants Fast Track Designation to NG-350A For pMMR Rectal Cancer